Minimal Invasive Surgery for Gastric Subepithelial Tumor

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The investigators conducted a retrospective study of those patients with gastric SETs receiving ER or LR at the operative theater in the single institution from January 2013 to December 2021. Medical records were retrospectively reviewed to define patient/tumor characteristics and operative outcomes.

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT02042079` - Endoscopic Full Thickness Resection With Laparoscopic Assistance	Phase 1
	Completed	`NCT03037034` - Novel Endoscopic Resection of Upper Gastrointestinal Subepithelial Tumors Originating From the Muscularis Propria	N/A

NCT number	NCT05452265
Study type	Observational
Source	Changhua Christian Hospital
Contact
Status	Completed
Phase
Start date	January 1, 2013
Completion date	December 31, 2021

Minimal Invasive Surgery for Gastric Subepithelial Tumor

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms